Zobrazeno 1 - 10
of 1 603
pro vyhledávání: '"Toni K Choueiri"'
Autor:
Thomas Powles, Laurence Albiges, David F McDermott, Michael B Atkins, Toni K Choueiri, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Martin H Voss, Hans J Hammers, Chung-Han Lee, Robert J Motzer, Yoshihiko Tomita, Nizar M Tannir, Meredith M Regan, Charlene M Mantia, Lisa Rosenblatt, Opeyemi A Jegede
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Immunotherapy can be associated with prolonged disease control even after cessation of treatment without the need for further cancer-directed therapy. Treatment-related adverse events (TRAEs) can also persist after discontinuation of thera
Externí odkaz:
https://doaj.org/article/e929a9c890ec467cac7b04eb3f99fada
Autor:
Lucia Kwak, So Yeon Kim, Guru Sonpavde, Elad Sharon, Abdul Rafeh Naqash, Alessio Cortellini, Rana R McKay, Toni K Choueiri, Thomas Marron, Amin H Nassar, Jeffrey A Sparks, Kaushal Parikh, Frank Aboubakar Nana, Jenny Linnoila, Shruti Gupta, Nicole R LeBoeuf, Elio Adib, Ahmad Al-Hader, Edward El-Am, Dory Freeman, Ahmed Bilal Khalid, Marita Salame, Elias Bou Farhat, Arjun Ravishankar, Bachar Ahmad, David Kaldas, Andrea Malgeri, Ole-Petter R Hamnvik, Thomas Dilling, Elie Najem, Talal El Zarif, Serena Rahme, Caiwei Zhong, Tarek H Mouhieddine
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns. Moreover, real-world data on efficacy and safety is scarce.Methods In this retrospective s
Externí odkaz:
https://doaj.org/article/e3a36a44dc60429b90c5ae6bfb360660
Autor:
Sabina Signoretti, Toni K Choueiri, Cloud Paweletz, Kun Huang, Yufei Wang, Gordon Freeman, Alicia Buck, Gabriella Kastrunes, Marion Grimaud, Atef Fayed, Luann Zerefa, Brandon Piel, Elena Ivanova, Miriam Ficial, Jon Wee, David Barbie, Wayne Marasco, Andras-Gabor Miklosi, Tran Thai, Ming-Ru Wu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/1aff22051bf348cc9e22b6ddf72ca71c
Autor:
Lucia Kwak, So Yeon Kim, Elad Sharon, Abdul Rafeh Naqash, Alessio Cortellini, Toni K Choueiri, Rana Mckay, Jeffrey A Sparks, Kaushal Parikh, Frank Aboubakar Nana, Jenny Linnoila, Shruti Gupta, Nicole R LeBoeuf, Elio Adib, Amin Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena J Rahme, Marita Salame, Elias Bou Farhat, Edward El Am, Arjun Ravishankar, Bachar Ahmad, David Kaldas, Andrea Malgeri, Ole-Petter R Hamnvik, Thomas Dilling, Elie Najem, Guru P Sonpavde
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/df99a0c739d64783afe5458e630339d9
Autor:
Wei Wei, Michael Hurwitz, Sabina Signoretti, Lucia Jilaveanu, Toni K Choueiri, David L Rimm, Adebowale Adeniran, Sandra Martínez, Harriet M Kluger, David A Schoenfeld, Myrto Moutafi, Dijana Djureinovic, Ross D Merkin, David A Braun, Fabio Parisi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background The tumor microenvironment (TME) contributes to cancer progression and treatment response to therapy, including in renal cell carcinoma (RCC). Prior profiling studies, including single-cell transcriptomics, often involve limited sample siz
Externí odkaz:
https://doaj.org/article/9b38124075304f5f862a35be425f0ea0
Autor:
Chung-Wei Lee, Thomas Powles, Sabina Signoretti, David F McDermott, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients
Externí odkaz:
https://doaj.org/article/635447aa98714bc2a7c7b60e0478a8aa
Autor:
Jin Yao, Thomas Powles, David F McDermott, Toni K Choueiri, Petra Ross-MacDonald, Simon Papillon-Cavanagh, Robert J Motzer, M Brent McHenry, Megan Wind-Rotolo, Ron Ammar, Yann-Alexandre Vano, Saurabh Gupta, Celine Han, Shruti S Saggi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line therapy for advanced clear-cell renal cell carcinoma (RCC). An unmet need exists
Externí odkaz:
https://doaj.org/article/1e556bbcc49144c39a159ece4d4fdec1
Autor:
David F McDermott, Gordon J Freeman, Toni K Choueiri, Petra Ross-MacDonald, F Stephen Hodi, Megan Wind-Rotolo, Long Yuan, Kathleen M Mahoney, Linan Song, Eliseo Veras
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/7c93c3e786c84292b00ec79f0d4a49f9
Autor:
Mario Sznol, Toni K Choueiri, Scott D Chasalow, Petra Ross-MacDonald, Simon Papillon-Cavanagh, Alice M Walsh, Megan Wind-Rotolo, Ron Ammar, Peter M Szabo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunothera
Externí odkaz:
https://doaj.org/article/2e6e7ac70cb64051a3880d53c7fc409f
Autor:
Howard Gurney, Thomas Powles, Laurence Albiges, Camillo Porta, Toni K Choueiri, Marc-Oliver Grimm, Elizabeth R Plimack, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Philippe Barthélémy, Christian K Kollmannsberger, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir, Mauricio Burotto, Daniel Castellano
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Purpose To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell
Externí odkaz:
https://doaj.org/article/f54750c49b2c4a85a39b1e7b5272d449